Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH82131D
- Pages: 64
- October 2018
- Region : Asia
- GlobalData
- Equity Research Report
- Details
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Details
Summary
Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company's pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei's NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. It also discovers and develops pharmaceutical products targeting G protein-coupled receptors. The company provides treatment for Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through its office located in London, the UK. Sosei is headquartered in Tokyo, Japan.
Sosei Group Corp (4565)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Heptares Therapeutics Raises USD 21 Million In Series B Financing 15
Partnerships 16
Heptares Therapeutics Enters into Research Agreement with Imperial College London 16
Heptares Therapeutics Enters into Research Agreement with Juntendo University 17
Heptares Therapeutics and PeptiDream Enter into Agreement 18
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21
Jitsubo Enters into Agreement with Heptares Therapeutics 22
Heptares Therapeutics and leadXpro Enter into Agreement 23
Heptares Therapeutics to Form Partnership with Kymab 24
Heptares Therapeutics Enters into Agreement with Pfizer 25
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26
Sosei Plans to Enter into Agreement with Novartis 27
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30
Heptares Therapeutics Extends Collaboration with the UK Medical Research 31
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32
Licensing Agreements 33
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Equity Offering 37
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42
Asset Transactions 43
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Acquisition 44
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp-Key Competitors 50
Sosei Group Corp-Key Employees 51
Sosei Group Corp-Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Recent Developments 54
Financial Announcements 54
Nov 09, 2017: Sosei Group: Consolidated Financial Results for the Second Period FY2017 (IFRS) 54
Corporate Communications 58
Jun 04, 2018: Sosei Announces Appointment of Chris Cargill as Interim CFO 58
Jan 19, 2018: Sosei Group Announces Resignation Of Fiona Marshall As Chief Scientific Officer 59
Jan 19, 2018: Changes in Executive Management at Sosei 60
Product News 61
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 61
Other Significant Developments 62
Feb 02, 2018: Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts 62
Jan 26, 2017: Achievement of sales milestone for COPD products 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List Of Figure
List of Figures
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12
List Of Table
List of Tables
Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Heptares Therapeutics Raises USD 21 Million In Series B Financing 15
Heptares Therapeutics Enters into Research Agreement with Imperial College London 16
Heptares Therapeutics Enters into Research Agreement with Juntendo University 17
Heptares Therapeutics and PeptiDream Enter into Agreement 18
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21
Jitsubo Enters into Agreement with Heptares Therapeutics 22
Heptares Therapeutics and leadXpro Enter into Agreement 23
Heptares Therapeutics to Form Partnership with Kymab 24
Heptares Therapeutics Enters into Agreement with Pfizer 25
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26
Sosei Plans to Enter into Agreement with Novartis 27
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30
Heptares Therapeutics Extends Collaboration with the UK Medical Research 31
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp, Key Competitors 50
Sosei Group Corp, Key Employees 51
Sosei Group Corp, Other Locations 52
Sosei Group Corp, Subsidiaries 52
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
Products and Companies
Products
Sosei Group Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Summary
Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company's pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei's NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. It also discovers and develops pharmaceutical products targeting G protein-coupled receptors. The company provides treatment for Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through its office located in London, the UK. Sosei is headquartered in Tokyo, Japan.
Sosei Group Corp (4565)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Heptares Therapeutics Raises USD 21 Million In Series B Financing 15
Partnerships 16
Heptares Therapeutics Enters into Research Agreement with Imperial College London 16
Heptares Therapeutics Enters into Research Agreement with Juntendo University 17
Heptares Therapeutics and PeptiDream Enter into Agreement 18
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21
Jitsubo Enters into Agreement with Heptares Therapeutics 22
Heptares Therapeutics and leadXpro Enter into Agreement 23
Heptares Therapeutics to Form Partnership with Kymab 24
Heptares Therapeutics Enters into Agreement with Pfizer 25
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26
Sosei Plans to Enter into Agreement with Novartis 27
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30
Heptares Therapeutics Extends Collaboration with the UK Medical Research 31
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32
Licensing Agreements 33
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Equity Offering 37
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42
Asset Transactions 43
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Acquisition 44
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp-Key Competitors 50
Sosei Group Corp-Key Employees 51
Sosei Group Corp-Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Recent Developments 54
Financial Announcements 54
Nov 09, 2017: Sosei Group: Consolidated Financial Results for the Second Period FY2017 (IFRS) 54
Corporate Communications 58
Jun 04, 2018: Sosei Announces Appointment of Chris Cargill as Interim CFO 58
Jan 19, 2018: Sosei Group Announces Resignation Of Fiona Marshall As Chief Scientific Officer 59
Jan 19, 2018: Changes in Executive Management at Sosei 60
Product News 61
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 61
Other Significant Developments 62
Feb 02, 2018: Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts 62
Jan 26, 2017: Achievement of sales milestone for COPD products 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List Of Figure
List of Figures
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12
List Of Table
List of Tables
Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Heptares Therapeutics Raises USD 21 Million In Series B Financing 15
Heptares Therapeutics Enters into Research Agreement with Imperial College London 16
Heptares Therapeutics Enters into Research Agreement with Juntendo University 17
Heptares Therapeutics and PeptiDream Enter into Agreement 18
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21
Jitsubo Enters into Agreement with Heptares Therapeutics 22
Heptares Therapeutics and leadXpro Enter into Agreement 23
Heptares Therapeutics to Form Partnership with Kymab 24
Heptares Therapeutics Enters into Agreement with Pfizer 25
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26
Sosei Plans to Enter into Agreement with Novartis 27
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30
Heptares Therapeutics Extends Collaboration with the UK Medical Research 31
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp, Key Competitors 50
Sosei Group Corp, Key Employees 51
Sosei Group Corp, Other Locations 52
Sosei Group Corp, Subsidiaries 52
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Products
Sosei Group Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Related Reports
Page 234 | 
September 2019
Page 140 | July 2019
Page 181 | July 2019
Page 130 | May 2019
Page 155 | April 2019